You are here: Industry Insights > Allergan

News List

Allergan pulls ads from Fox show after host questions Muslim rep's loyalty fiercepharma
March 15, 2019
Another Fox show is facing drug advertiser dropouts this week. Allergan is the latest to jumped ship on a Fox show, while Novo Nordisk said it is “re-evaluating” its ad support several days after Jeanine Pirro made controversial comments about a Muslim Co
Allergan files anti-CGRP migraine drug in the US pharmatimes
March 12, 2019
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop firstwordpharma
March 11, 2019
A major Allergan pipeline candidate may have failed phase 3 on Wednesday, but investors cheered the news. The reason? They’re anticipating a split.
Allergan activists, ready for 'disruptive action,' call for split, sale, executive changes firstwordpharma
March 11, 2019
After Allergan revealed Wednesday that a major pipeline prospect had flunked a phase 3 trial, analysts predicted activist investors demanding change would ratchet up pressure on the company’s executives.
Allergan's rapastinel fails to meet primary endpoints in Phase III depression studies firstwordpharma
March 07, 2019
Allergan on Wednesday announced topline results from the Phase III RAP-MD-01, RAP-MD-02 and RAP-MD-03 studies of the major depressive disorder (MDD) drug candidate rapastinel, saying treatment arms did not differentiate from placebo on the primary and key
Hedge funder renews call for Allergan CEO-chairman split, citing 'chronic underperformance' fiercepharma
February 24, 2019
Last year, Appaloosa and Senator Investment Group wrote to Allergan’s board requesting a series of changes, including a split of the CEO and chairman roles both currently held by Brent Saunders. And they're not happy about being ignored.
Under-pressure Allergan backs a CEO-chairman job split—just not right now fiercepharma
February 24, 2019
Amid investor pressure to split up its CEO and chairman roles, embattled Allergan is giving in—but only a bit.
Amgen, Allergan Announce Positive Top-Line Results from ABP 798 Study americanpharmaceuticalreview
January 25, 2019
Amgen and Allergan announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798....
Allergan and Mohawk tribe ask SCOTUS to review controversial Restasis patent licensing deal fiercepharma
January 17, 2019
When Allergan transferred six Restasis patents to the Saint Regis Mohawk tribe in 2017 in a bid to shield the dry-eye treatment from generic competition, it was widely maligned by everyone from industry insiders to tech giants like Microsoft. And in July,
“All-powerful Drug” of Allergan: Botox Pushed Clinical Trial, MDD Clinical Protocol Postponed PharmaSources/Zhulikou431
January 09, 2019
Phase III clinical trial of Allergan’s Botox for major depressive disorder (MDD) will be pushed to the second half of 2019 (H2 2019), said the spokesperson of the company recently.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page